ClinicalTrials.gg
CompletedNCT06186752Updated Oct 29, 2026

Feasibility Test of Action Planning in Pediatric IBD

An interventional study of MyIBD in Inflammatory Bowel Diseases, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to participants aged 13 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Health services research

How we know

Updated Oct 29, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
13 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
145th of 327
61 · median 50
Started
2024
with 20 others
No phase
131 of 463
35 open now
Registered
392nd of 463
by date
Lead sponsor
9 of 463
University of North Carolina, Chapel Hill

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 145th largest by enrollment of the 327 interventional ones that give a count, is one of 21 that started in 2024, is one of 131 with no phase, and was the 392nd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 13 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

The goal of this interventional study is to test the feasibility of a new communication tool, call MyIBD, in youth ages 13 to 19 years with inflammatory bowel disease. The main question[s] it aims to answer are:

  • Is the MyIBD communication tool feasible to use in everyday clinical practice?
  • Does the MyIBD tool have potential to improve patients' self-management skills and the quality of care they receive?

Participants who receive the MyIBD intervention will complete surveys about their care at three times points - at study enrollment, at 6 months, and at 12 months. The surveys will help the research team learn about the feasibility of using MyIBD in practice and about any effects on patients' self-management skills and quality of care.

Researchers will compare those receiving a MyIBD document to a randomly selected control group (patients receiving usual care for pediatric inflammatory bowel disease) to see if self-management skills and quality of care differ between the groups.

Read the detailed description

Quality of care for youth with chronic disease suffers because of gaps in care coordination and communication among patients/families and multiple health care providers. As youth with inflammatory bowel disease (IBD) have preventive and acute care needs beyond those of peers, IBD provides an excellent use case to evaluate interventions to enhance coordination and improve quality. Electronic health records (EHRs) have unfulfilled potential to facilitate coordination and effective action among teams of providers and families. This project leverages web-based and mobile phone application access points to share patient-specific information from an IBD center's EHR. The intervention, MyIBD, has been developed with systematic input from patients, families, and providers. Our objective is to assess the feasibility of delivering tailored guidance on IBD-related health needs to families and care team members using a low-cost, low-risk health communication innovation using existing health information technology. The rationale is that brief, actionable, individually tailored guidance from IBD specialists to families and other providers will support decisions about seeking and providing timely preventive and acute care. Though the intervention builds on prior work and evidence and has been pilot tested, it requires feasibility testing in practice prior to large-scale evaluation. We will assess feasibility of MyIBD through a pilot randomized, controlled trial at one site (n=60). The study has three research aims: (1) assess the feasibility of a rollout effectiveness trial design; (2) assess the feasibility and acceptability of implementing MyIBD in a pediatric IBD clinic; (3) explore the feasibility of MyIBD to improve (a) care quality measures collected from participants and the EHR and (b) patient self-management. In Aim 1 we will assess subject recruitment, randomization, retention, intervention completion, and contamination of control subjects using a study log. For Aim 2 we will use interviews (will take place after completion of the feasibility trial) and surveys to learn about barriers and facilitators of adoption by IBD clinics and acceptability and appropriateness from the perspectives of patients/families and care providers. For Aim 3 we will use surveys and medical record data to explore change over time in family-reported care quality, patient self-management, and completion of guideline-supported quality indicators for pediatric IBD for intervention and control groups. This project is innovative in seeking to change the default ways that care team members share information and address shared responsibilities. MyIBD targets well-described barriers to coordination and incorporates behavioral strategies of individual tailoring, family participation, expert modeling, and facilitation to streamline information delivery and enhance its relevance, accessibility, and actionability. The proposed study is significant because of its potential to improve health through a low-cost intervention to enhance use of existing health information technology. The study's findings could provide a framework for EHR-supported quality improvements through learning health system research across a range of childhood-onset chronic diseases.

03

Conditions studied

  • Inflammatory Bowel Diseases
04

Who can participate

Ages eligible
13 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 13-19 years old at time of recruitment; AND
  • diagnosis at least 3 months earlier of Crohn's disease, ulcerative colitis, or indeterminate colitis (to exclude families who have not had sufficient time to become familiar with condition and/or clinic personnel); AND
  • receiving ongoing care at UNC (at least one visit in the past year)

Exclusion criteria

Exclusion Criteria:

  • speaker of a language other than English or Spanish
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    MyIBD

    Each participant randomized to the intervention arm (MyIBD) will receive an individually tailored MyIBD document within a week of a scheduled outpatient clinic visit. The MyIBD document will be prepared by the patient's usual, assigned nurse coordinator together with the study's clinical champion (a nurse practitioner in the IBD program). Participants will receive a copy of the MyIBD document with language suggesting that they use it to guide decisions about care in between appointments. Each participant's primary care provider will also receive a copy of the MyIBD document. The nurse coordinator will send reminder messages to intervention-group participants (using the electronic patient portal) to access and use their MyIBD document at 1-2 months, 3-4 months, 7-8 months, and 11-12 months after initial plan creation.

    Behavioral: MyIBD

  • No intervention
    Usual Care

    Each participant randomized to the control group will receive usual care in the pediatric IBD program. They will be eligible to receive a MyIBD document after completing the study (12 months after enrollment).

Interventions

  • BehavioralMyIBD

    MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.

06

What researchers measure

Primary outcomes

  1. Number of overall participants recruited and randomized

    Number (0-60) will be an indicator of feasibility of implementing MyIBD in practice.

    Time frame: Measured and reported at the end of study year 1

  2. Number of intervention group participants who receive a MyIBD document

    Number (0-30) of intervention-group participants who receive a MyIBD document will estimate the degree of completion of the intervention in practice.

    Time frame: Measured and reported at the end of study year 1

  3. Number of overall participants retained through baseline survey

    Number (0-60) of participants who complete the baseline survey

    Time frame: Measured and reported at the end of study year 1

  4. Number of overall participants retained through 6-month survey

    Number (0-60) of participants who complete the 6-month survey

    Time frame: Measured and reported at the mid-point of study year 2

  5. Number of overall participants retained through 12-month survey

    Number (0-60) of participants who complete the 12-month survey

    Time frame: Measured and reported at end of study year 2

  6. Number of control group participants who receive a MyIBD document

    Number (0-30) of control-group participants who (inappropriately) receive a MyIBD document is an indicator of contamination, or spreading the intervention in practice to the control group.

    Time frame: Measured and reported at the end of study year 1

  7. Number of intervention group participants who agree or completely agree that MyIBD is an acceptable intervention using the Acceptability of Intervention Measure

    Measured in the 12-month participant survey using the Acceptability of Intervention Measure (AIM), a four-item scale with five Likert-type response options from 1=Completely disagree to 5=Completely agree. Item scores are averaged to yield a scale score, with 1 indicating the lowest level of acceptability and 5 indicating the highest level.

    Time frame: Reported at the end of study year 2

  8. Number of intervention group participants who agree or completely agree that MyIBD is an appropriate intervention using the Intervention Appropriateness Measure

    Measured in the 12-month participant survey using the Intervention Appropriateness Measure (IAM), a four-item scale with five Likert-type response options from 1=Completely disagree to 5=Completely agree. Item scores are averaged to yield a scale score, with 1 indicating the lowest level of appropriateness and 5 indicating the highest level.

    Time frame: Reported at the end of study year 2

Secondary outcomes

  1. Mean self-management score on the Partners in Health scale at baseline

    Measured in the baseline participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill.

    Time frame: Measured in each participant's baseline survey; reported at end of study year 1

  2. Mean self-management score on the Partners in Health scale at 6 months

    Measured in the 6-month participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill.

    Time frame: Measured in each participant's 6-month survey; reported at end of study year 2

  3. Mean self-management score on the Partners in Health scale at 12 months

    Measured in the 12-month participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill.

    Time frame: Measured in each participant's 12-month survey; reported at end of study year 2

  4. Mean perceived Quality of Care score at baseline using the Patient Assessment of Chronic Illness Care survey

    Measured in the baseline participant survey using the Patient Assessment of Chronic Illness Care scale, a 20-item survey with 5 Likert-type responses from 1=None of the time to 5=Always. Item scores are averaged to yield an overall scale score between 1 and 5, with 1 indicating the lowest perceived care quality and 5 indicating the highest.

    Time frame: Measured in each participant's baseline survey; reported at end of study year 1

  5. Mean perceived Quality of Care score at 12 months using the Patient Assessment of Chronic Illness Care survey

    Measured in the 12-month participant survey using the Patient Assessment of Chronic Illness Care scale, a 20-item survey with 5 Likert-type responses from 1=None of the time to 5=Always. Item scores are averaged to yield an overall scale score between 1 and 5, with 1 indicating the lowest perceived care quality and 5 indicating the highest.

    Time frame: Measured in each participant's 12-month survey; reported at end of study year 2

Other outcomes

  1. Number of overall participants who completed a primary care health supervision visit in the past year, baseline

    Number (0-60) of participants who report having a primary care health supervision visit with a primary care provider in the past year

    Time frame: Measured by self-report in baseline survey; reported at end of study year 1

  2. Number of overall participants who completed a primary care health supervision visit in the past year, 12 months

    Number (0-60) of participants who report having a primary care health supervision visit with a primary care provider in the past year

    Time frame: Measured by self-report in 12-month survey; reported at end of study year 2

  3. Number of overall participants who completed special vaccine recommendations, baseline

    Number (0-unknown) of participants who report having completed all special vaccines recommended by IBD clinician (such as Hepatitis B booster dose, pneumococcal polysaccharide vaccine)

    Time frame: Measured by self-report in baseline survey; reported at end of study year 1

  4. Number of overall participants who completed special vaccine recommendations, 12 months

    Number (0-unknown) of participants who report having completed all special vaccines recommended by IBD clinician (such as Hepatitis B booster dose, pneumococcal polysaccharide vaccine)

    Time frame: Measured by self-report in 12-month survey; reported at end of study year 2

  5. Number of overall participants who participated in mood disorder screening in the past year, baseline

    Number (0-60) of participants who report participating in any mood disorder screening in the past year

    Time frame: Measured by self-report in baseline survey; reported at end of study year 1

  6. Number of overall participants who participated in mood disorder screening in the past year, 12 months

    Number (0-60) of participants who report participating in any mood disorder screening in the past year

    Time frame: Measured by self-report in 12-month survey; reported at end of study year 2

  7. Average number of non-injury-related visits to an emergency department (ED) in the past year, baseline

    Total count of non-injury-related ED visits by participants in the past year divided by the total number of participants

    Time frame: Measured by self-report in baseline survey; reported at end of study year 1

  8. Average number of non-injury-related visits to an emergency department (ED) in the past year, 12 months

    Total count of non-injury-related ED visits by participants in the past year divided by the total number of participants

    Time frame: Measured by self-report in 12-month survey; reported at end of study year 2

07

Study locations

1 site
  • University of North Carolina-Chapel Hill School of Medicine
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will become 9 to 36 months following publication and will remain available as long as the principal investigator remains actively working.

Access criteria: See Plan Description section above for IRB or similar authorization prior to access. Once those criteria have been met, an interested investigator may contact the study PI by email (dejong@med.unc.edu); the PI would arrange for deidentified data sharing in accordance with university policy.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Mar 2026, 24 months.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 24 months is below that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Apr 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Jan 2, 2024
StartActual
Feb 5, 2024
Primary completionActual
Mar 1, 2026
CompletionActual
Apr 5, 2026was Mar 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Study completion
Mar 2026→Apr 5, 2026 (actual)
Oct 29, 2026
Enrollment
60 (estimated)→61 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Study completion Mar 2026→Apr 5, 2026 (now actual)
    Enrollment 60 (estimated)→61 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06186752
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Feb 5, 2024
Primary completion
Mar 1, 2026
Completion
Apr 5, 2026
Last update
Oct 29, 2026

Study contacts

Neal deJong, MD
principal investigator · UNC-Chapel Hill School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion